Prognostic factors in endometrial carcinoma

Journal of Obstetrics and Gynaecology Research

Volumn 34, Issue 5, 2008, Pages 776-783

  Uharček, Peter ^a,b  

^a FACULTY HOSPITAL   (Slovakia)

^b Hospital Nitra   (Slovakia)

Author keywords

Clinicopathological factors; Endometrial carcinoma; Prognosis

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; CELL ADHESION MOLECULE; ESTROGEN; ESTRONE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; STEROID RECEPTOR; TAMOXIFEN;

AGE; ANGIOGENESIS; ASCITES FLUID CYTOLOGY; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; ENDOMETRIUM CARCINOMA; HIGH RISK POPULATION; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; LIFE EXPECTANCY; LYMPH NODE METASTASIS; MICROSATELLITE INSTABILITY; OBESITY; ONCOGENE NEU; PARITY; PLOIDY; POSTMENOPAUSE; PROGNOSIS; REVIEW; SEXUAL BEHAVIOR;

CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; PROGNOSIS; RISK FACTORS;

EID: 52049098489     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2008.00796.x     Document Type: Review

References (77)

1. Bray F, Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: Underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005 14 : 1132 1142.
2. Redecha M, Nižňanská Z, Korbel' M. Výskyt zhubných nádorov tela maternice na Slovensku v rokoch 1990-2000. Gynekol Prax 2004 2 : 194 199.
3. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaec 1989 96 : 889 892.
4. Boronow RC, Morrow CP, Creasman WT. Surgical staging in endometrial cancer: Clinical-pathologic findings of a prospective study. Obstet Gynecol 1984 63 : 825 832.
5. Creasman WT, Morrow CP, Bundy BN et al. Surgical pathologic spread patterns of endometrial cancer (a GOG study). Cancer 1987 60 : 2035 2041.
6. Morrow CP, Bundy BN, Kurman RJ et al. Relationship between surgical-pathologic risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol 1991 40 : 55 65.
7. Gruber SB, Thompson WD. A population-based study of endometrial cancer and familial risk in younger women. Cancer Epidemiol Biomarkers Prev 1996 5 : 411 417.
8. Dunlop MG, Farrington SM, Carothers AD et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997 6 : 105 110.
9. Parc YR, Halling KC, Burgart LJ et al. Microsatellite instability and hMLH1/hMSH2 expression in young endometrial carcinoma patients: Associations with family history and histopathology. Int J Cancer 2000 86 : 60 66.
10. Ota T, Yoshida M, Kimura M, Kinoshita K. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer 2005 15 : 657 662.
11. Jolly S, Vargas CE, Kumar T et al. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Gynecol Oncol 2006 103 : 87 93.
12. Yamazawa K, Seki K, Matsui H, Kihara M, Sekiya S. Prognostic factors in young women with endometrial carcinoma: A report of 20 cases and review of literature. Int J Gynecol Cancer 2000 10 : 212 222.
13. Abeler VM, Kjørstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991 67 : 3093 3103.
14. Britton LC, Wilson TO, Gaffey TA, Lieber MM, Wieand HS, Podratz KC. Flow cytometric DNA analysis of stage I endometrial carcinoma. Gynecol Oncol 1989 34 : 317 322.
15. Creasman WT. Adenocarcinoma of the uterus. In : DiSaia PJ, Creasman WT (eds). Clinical Gynecologic Oncology, 7th edn. Philadelphia, PA : Mosby Elsevier, 2007 147 184.
16. Salvesen HB, Akslen LA, Albrektsen G, Iversen OE. Poorer survival of nulliparous women with endometrial carcinoma. Cancer 1998 82 : 1328 1333.
17. Deligdisch L, Holinka CF. Endometrial carcinoma: Two diseases? Cancer Detect Prev 1987 10 : 237 246.
18. Bokhman JV. Two pathogenic types of endometrial carcinoma. Gynecol Oncol 1983 15 : 10 17.
19. Gates EJ, Hirschfield L, Matthews RP, Yap OWS. Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium. J Natl Med Assoc 2006 98 : 1814 1822.
20. Abeler VM, Kjørstad KE. Endometrial adenocarcinoma with squamous differentiation. Cancer 1992 69 : 488 495.
21. Zaino RJ, Kurman RJ, Brunetto VL et al. Villoglandular adenocarcinoma of the endometrium: A clinicopathological study of 61 cases. A Gynecologic Oncology Group study. Am J Surg Pathol 1998 22 : 1379 1385.
22. Ross JC, Eifel PJ, Cox RS et al. Primary mucinous adenocarcinoma of the endometrium: A clinicopathological histochemical study. Am J Surg Pathol 1983 7 : 715 729.
23. International Federation of Gynecology and obstetrics (FIGO): Announcements. FIGO stages: 1998 revision. Gynecol Oncol 1999 35 : 125 127.
24. Silverberg et al. Epithelial tumors of the uterine corpus and related lesions. In : Tavassoli FA, Devilee P (eds). WHO Classification of Tumours, Pathology and Genetics, Tumours of the Breast and Female Genital Tract. Geneva : WHO Press, 2003 221 232.
25. Zaino RJ, Kurman RJ, Herbold D et al. The significance of squamous differentiation in endometrial carcinoma. Cancer 1991 68 : 2293 2302.
26. Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM. A binary architectural grading system for uterine endoemetrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advanced-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol 2000 24 : 1201 1208.
27. Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Endometrial cancer: Predictors of peritoneal failure. Gynecol Oncol 2003 89 : 236 242.
28. Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Assessment of prognostic factors in stage IIIA endometrial cancer. Gynecol Oncol 2002 86 : 38 44.
29. Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol 2002 84 : 437 442.
30. Cohn DE, Horowitz NS, Mutch DG, Kim SM, Manolitsas T, Fowler JM. Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer? Gynecol Oncol 2002 87 : 243 246.
31. Briët JM, Hollema H, Reesink N et al. Lymphvascular space involvement: An independent prognostic factor in endometrial cancer. Gynecol Oncol 2005 96 : 799 804.
32. Hachisuga T, Fukuda K, Iwasaka T, Hirakawa T, Kawarabayashi T, Tsuneyoshi M. Carcinoma of the lower uterine segment. Int J Gynecol Pathol 1989 8 : 26 53.
33. Eltabbakh GH, Moore AD. Survival of women with surgical stage II endometrial cancer. Gynecol Oncol 1999 74 : 80 85.
34. Jordan LB, Al-Nafussi A. Clinicopathological study of the pattern and significance of cervical involvement in cases of endometrial adenocarcinoma. Int J Gynecol Cancer 2002 12 : 42 48.
35. Mariani A, Sebo TJ, Webb MJ et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prev 2003 27 : 434 441.
36. Greven KM, Curran WJ Jr., Whittington R et al. Analysis of failure patterns in stage III endometrial carcinoma and therapeutic implications. Int J Radiat Oncol Biol Phys 1989 17 : 35 39.
37. Connell PP, Rotmensch J, Waggoner S, Mundt AJ. The significance of adnexal involvement in endometrial carcinoma. Gynecol Oncol 1999 74 : 74 79.
38. Ashman JB, Connell PP, Yamada D, Rotmensch J, Waggoner SE, Mundt AJ. Outcome of endometrial carcinoma patients with involvement of the uterine serosa. Gynecol Oncol 2001 82 : 338 343.
39. Mazurka JL, Krepart GV, Lotocki RJ. Prognostic significance of positive peritoneal cytology in endometrial carcinoma. Am J Obstet Gynecol 1988 158 : 303 306.
40. Turner DA, Gershenson DM, Atkinson N, Sneige N, Wharton AT. The prognostic significance of peritoneal cytology for stage I endometrial cancer. Obstet Gynecol 1989 74 : 775 780.
41. Aoki Y, Kase H, Watanabe M, Sato T, Kurata H, Tanaka K. Stage III endometrial cancer: Analysis of prognostic factors and failure patterns after adjuvant chemotherapy. Gynecol Oncol 2001 83 : 1 5.
42. Hirai Y, Takeshima N, Kato T, Hasumi K. Malignant potential of positive peritoneal cytology in endometrial cancer. Obstet Gynecol 2001 97 : 725 728.
43. Obermair A, Geramou M, Tripcony L, Nicklin JL, Perrin L, Crandon AJ. Peritoneal cytology: Impact on disease-free survival in clinical stage I endometrioid adenocarcinoma of the uterus. Cancer Lett 2001 164 : 105 110.
44. Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet 2003 83 (Suppl 1 79 118.
45. Partridge EE, Shingleton HM, Menck HR. The National Cancer Data Base report on endometrial cancer. J Surg Oncol 1996 61 : 111 123.
46. Mariani A, Webb MJ, Keeney GL et al. Stage IIIC endometrioid corpus cancer includes distinct subgroups. Gynecol Oncol 2002 87 : 112 117.
47. Chan JK, Kapp DS, Cheung MK et al. The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients. Br J Cancer 2007 97 : 605 611.
48. Geisinger KR, Marshall RB, Kute TE, Homesley HD. Correlation of female sex steroid hormone receptors with histologic and ultrastructural differentiation in adenocarcinoma of the endometrium. Cancer 1986 58 : 1506 1517.
49. Kadar N, Malfetano JH, Homesley HD. Steroid receptor concentrations in endometrial carcinoma: Effect on survival in surgically staged patients. Gynecol Oncol 1993 50 : 281 286.
50. Jeon YT, Park IA, Kim YB et al. Steroid receptor expressions in endometrial cancer: Clinical significance and epidemiological implication. Cancer Lett 2006 239 : 198 204.
51. Iversen OE, Utaaker E, Skaarland E. DNA ploidy and steroid receptors as predictors of disease course in patients with endometrial carcinoma. Acta Obstet Gynecol Scand 1988 67 : 531 537.
52. Sivridis E, Giatromanolaki A, Koukourakis M, Anastasiadis P. Endometrial carcinoma: Association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch 2001 438 : 470 477.
53. Zaino RJ, Davis AT, Ohlsson-Wilhelm BM et al. DNA content is an independent prognostic indicator in endometrial adenocarcinoma. A Gynecologic Oncology Group study. Int J Gynecol Pathol 1998 17 : 312 319.
54. Larson DM, Berg R, Shaw G et al. Prognostic significance of DNA ploidy in endometrial cancer. Gynecol Oncol 1999 74 : 356 360.
55. Lundgren C, Auer G, Frankendal B et al. Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma. Int J Gynecol Cancer 2002 12 : 110 118.
56. Nordstrom B, Strang P, Lindgren A et al. Carcinoma of the endometrium: Do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications? Int J Gynecol Pathol 1996 15 : 191 201.
57. Wimberger P, Hillemanns P, Kapsner T, Hepp H, Kimmig R. Evaluation of prognostic factors following flow-cytometric DNA analysis after cytokeratin labelling: II. Cervical and endometrial cancer. Anal Cell Pathol 2002 24 : 147 158.
58. Abulafia O, Triest WE, Sherer DM, Hansen CC, Ghezzi F. Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol 1995 86 : 479 485.
59. Kirschner CV, Alanis-Amezcua JM, Martin VG et al. Angiogenesis factor in endometrial carcinoma: A new prognostic indicator? Am J Obstet Gynecol 1996 174 : 1879 1882.
60. Salvesen HB, Iversen OE, Akslen LA. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res 1998 4 : 2779 2785.
61. Kaleli S, Kösebay D, Bese T et al. A strong prognostic variable in endometrial carcinoma: Flow cytometric S-phase fraction. Cancer 1997 79 : 944 951.
62. Stefansson IM, Salvesen HB, Immervoll H, Akslen LA. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 2004 44 : 472 479.
63. Rolitsky CD, Theil KS, McGaughy VR et al. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynaecol Pathol 1999 18 : 138 143.
64. Reinartz JJ, George E, Lindgren BR et al. Expression of p53, transforming growth factor receptor, and c-erb B2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994 25 : 1075 1083.
65. Slomovitz BM, Broaddus RR, Burke TW et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004 22 : 3126 3132.
66. Backe J, Gassel AM, Krebs S et al. Immunohistochemically detected HER-2/neu expression and prognosis in endometrial carcinoma. Arch Gynecol Obstet 1997 259 : 189 195.
67. Coronado PJ, Vidart JA, López-Asenjo JA et al. p53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression. Eur J Obstet Gynecol Reprod Biol 2001 98 : 103 108.
68. Heffner HM, Freedman AN, Asirwatham JE et al. Prognostic significance of p53, PCNA, and HER-2/neu in endometrial carcinoma. Eur J Gynaecol Oncol 1999 20 : 8 12.
69. Athanassiadou P, Athanassiades P, Grapsa D et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: A prospective immunocytochemical study. Int J Gynecol Cancer 2007 17 : 697 704.
70. Mariani A, Sebo TJ, Katzmann JA et al. Pretreatment assessment of prognostic indicators in endometrial cancer. Am J Obstet Gynecol 2000 182 : 1535 1544.
71. Inaba F, Kawamata H, Teramoto T, Fukasawa I, Inaba N, Fujimori T. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma. Oncol Rep 2005 13 : 17 24.
72. An HJ, Kim KI, Kim JY et al. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. Am J Surg Pathol 2007 31 : 846 853.
73. Caduff RF, Johnston CM, Svoboda-Newman SM et al. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996 148 : 1671 1678.
74. Basil JB, Goodfellow PJ, Rader JS et al. Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 2000 89 : 1758 1764.
75. MacDonald ND, Salvesen HB, Ryan A et al. Frequency and prognostic impact of microsatellite instability in a large populationbased study of endometrial carcinomas. Cancer Res 2000 15 : 1750 1752.
76. Mell LK, Meyer JJ, Tretiakova M et al. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res 2004 10 : 5546 5553.
77. Scholten AN, Aliredjo R, Creutzberg CL, Smit VT. Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma. Int J Gynecol Cancer 2006 16 : 1379 1385.